ISSN 0169-5002
Publisher: Elsevier
< previous issue | all issues | next issue >
Lung cancer and tobacco smoking pp. 167-181(15) Authors: Boyle P.; Maisonneuve P.
Increased radioresistance of an in vitro transformed human small cell lung cancer cell line pp. 183-198(16) Authors: Brodin O.; Arnberg H.; Bergh J.; Nilsson S.
Reliability and validity of the Functional Assessment of Cancer Therapy -- Lung (FACT-L) quality of life instrument pp. 199-220(22) Authors: Cella D.F.; Bonomi A.E.; Lloyd S.R.; Tulsky D.S.; Kaplan E.; Bonomi P.
CT scanning of bronchioloalveolar carcinoma: specific appearances pp. 221-230(10) Authors: Akata S.; Fukushima A.; Kakizaki D.; Abe K.; Amino S.
Cognitive deficits in patients with small cell lung cancer before and after chemotherapy pp. 231-235(5) Authors: Meyers C.A.; Byrne K.S.; Komaki R.
A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer pp. 237-246(10) Authors: Erkisi M.; Doran F.; Burgut R.; Kocabas A.
Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer pp. 247-257(11) Authors: Jacoulet P.; Breton J.-L.; Westeel V.; Mercier M.; Garnier G.; Depierre A.
Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung pp. 259-262(4) Authors: Fuentes R.; Dorca J.; Canals E.; Izquierdo A.; Beltran M.; Viladiu P.
Radiographic abnormalities and the risk of lung cancer among workers exposed to silica dust in Ontario pp. 265-265(1) Author: Finkelstein M.
Evolution of aerodigestive tract 13-cis-retinoid acid chemoprevention: The M.D. Anderson experience pp. 265-265(1) Authors: Hong W.; Benner S.; Lippman S.
Smoking habits and attitudes of medical students towards smoking and anti-smoking campaigns in the Faculty of Medicine, University of Istanbul, Turkey pp. 265-265(1) Authors: Cuhadaroglu C.; Erkan F.; Ertugrul E.
Bronchopulmonary precancerous and tumor diseases - Risk groups from the point of view of occupational medicine pp. 265-266(2) Authors: Baur X.; Marczynski B.; Rozynek P.; Voss B.
Exposure to environmental tobacco smoke and risk of lung cancer: The epidemiological evidence pp. 266-266(1) Authors: Tredaniel J.; Boffetta P.; Saracci R.; Hirsch A.
Passive smoking in the workplace: Classical and Bayesian meta-analyses pp. 266-266(1) Authors: Biggerstaff B.; Tweedie R.; Mengersen K.
Lung adenocarcinoma and indicators of asbestos exposure pp. 266-266(1) Authors: Mollo F.; Pira E.; Piolatto G.; Bellis D.; Burlo P.; Andreozzi A.
Radon and primary lung cancer pp. 266-266(1) Authors: Menard O.; Scheid P.; Anthoine D.; Martinet Y.
Risk of lung cancer among cigarette smokers in relation to tumor location pp. 266-266(1) Authors: Shimizu H.; Nagata C.; Tsuchiya E.; Nakagawa K.; Weng S.-Y.
Silica dust exposure and lung cancer pp. 266-267(2) Authors: Koskela R.-S.; Klockars M.; Laurent H.; Holopainen M.
Integrated optical density (IOD), syntactic structure analysis, and survival in operated lung carcinoma patients pp. 267-267(1) Authors: Kayser K.; Liewald F.; Kremer K.; Tacke M.
A mortality study of lung cancer among Swiss professional drivers: Accounting for the smoking related fraction by a multivariate approach pp. 267-267(1) Authors: Pfluger D.; Minder C.
Lung cancer incidence after exposure of rats to low doses of radon: Influence of dose rate pp. 267-267(1) Authors: Morlier J.; Morin M.; Monchaux G.; Fritsch P.; Pineau J.; Chameaud J.
Mortality of iron foundry workers. III. Lung cancer case-control study pp. 267-267(1) Authors: Andjelkovich D.; Shy C.; Brown M.; Janszen D.; Levine R.; Richardson R.
Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients pp. 267-267(1) Authors: Ryberg D.; Hewer A.; Phillips D.; Haugen A.
Deposition and retention of inhaled fibres: Effects on incidence of lung cancer and mesothelioma pp. 267-268(2) Author: Lippmann M.
Effect of superoxide dismutase and diethyldithiocarbamate on the induction of squamous cell carcinoma of lung with methylcholanthrene in rats pp. 268-268(1) Authors: Liu M.; Yu L.; Shu Q.
Primary carcinoids of the lungs - Asbestos dust-induced malignancies in the sense of occupational disease no. 4104 BeKV? pp. 268-268(1) Authors: Kraus T.; Kirchner T.; Raithel H.; Lehnert G.
Asthma and lung cancer by diesel exhaust pp. 268-268(1) Authors: Sagai M.; Ichinose T.
Lung cancer and cigarette smoking in women: A case-control study in Barcelona (Spain) pp. 268-268(1) Authors: Agudo A.; Barnadas A.; Pallares C.; Martinez I.; Fabregat X.; Rosello J.
Lung cancer mortality in a French cohort of hard-metal workers pp. 268-268(1) Authors: Lasfargues G.; Wild P.; Moulin J.; Hammon B.; Rosmorduc B.; Du Noyer C.
Dietary cholesterol, fat, and lung cancer incidence among older women: The Iowa Women's Health Study (United States) pp. 268-269(2) Authors: Wu Y.; Zheng W.; Sellers T.; Kushi L.; Bostick R.; Potter J.
Lung cancer in Estonia in 1968-87: Time trends and public health implications pp. 269-269(1) Authors: Aareleid T.; Leinsalu M.; Rahu M.; Baburin A.
Nuclear magnetic resonance relaxation times for human lung cancer and lung tissues pp. 269-269(1) Authors: Matsuura Y.; Shioya S.; Kurita D.; Ohta T.; Suda S.; Haida M.; Fukuzaki M.; Ohta Y.
Lung tumor induction in A/J mice and clastogenic effects in CD-1 mice of the sequence-selective DNA alkylating agents (+)-CC-1065 and (-)-CC-1065 pp. 269-269(1) Authors: Linseman D.; Branstetter D.; Yu R.; Aaron C.
Time-related effects of enzymatic disaggregation on model human lung carcinomas pp. 269-269(1) Authors: Howard R.; Shroyer K.; Marcell T.; Swanson L.; Pagura M.; Mulvin D.
Human papillomavirus type 18 DNA and E6-E7 mRNA are detected in squamous cell carcinoma and adenocarcinoma of the lung pp. 269-269(1) Authors: Kinoshita I.; Dosaka-Akita H.; Shindoh M.; Fujino M.; Akie K.; Kato M.
Detection of c-myc and c-sis mRNA in human non-small cell lung cancer pp. 269-270(2) Author: Kawamata O.
Cholecystokinin-B/gastrin receptor: A novel molecular probe for human small cell lung cancer pp. 270-270(1) Authors: Matsumori Y.; Katakami N.; Ito M.; Taniguchi T.; Iwata N.; Takaishi T.
Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer pp. 270-270(1) Authors: Fong K.; Zimmerman P.; Smith P.
Biologic characterization of pleural metastases from lung adenocarcinoma: Description of the new DV90 cell line pp. 270-270(1) Authors: Monti F.; Szymczuk S.; Chessa L.; Prudente S.; Nicoletti G.; Fattori P.
A GRP receptor antagonist which inhibits small cell lung cancer growth pp. 270-270(1) Authors: Moody T.; Venugopal R.; Zia F.; Patierno S.; Leban J.; McDermed J.
Human small cell lung cancer cells express high affinity naloxone-insensitive [125I]-endorphin binding sites pp. 270-270(1) Author: Taylor J.
Constitutive secretion of bioactive transforming growth factor 1 by small cell lung cancer cell lines pp. 270-270(1) Authors: Fischer J.; Darjes H.; Lahm H.; Schindel M.; Drings P.; Krammer P.
Cell type-specific regulation of p53 expression in non-small cell lung carcinoma cells pp. 270-271(2) Authors: Maxwell S.; Zhang W.
Expression of NSE and PGP 9.5 in non-small cell lung cancers pp. 271-271(1) Authors: Walker C.; Burnett H.; Kenyon W.; Spedding A.
Molecular pathogenesis of lung cancer: Implications for early diagnosis by new screening tests pp. 271-271(1) Author: Von Knebel Doeberitz M.
Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer pp. 271-271(1) Authors: Moscow J.; Schmidt L.; Ingram D.; Gnarra J.; Johnson B.; Cowan K.
Patterns of p53 mutations in squamous cell carcinoma of the lung: Acquisition at a relatively early age pp. 271-271(1) Authors: Zheng J.; Shu Q.; Li Z.-H.; Tsao J.-I.; Weiss L.; Shibata D.
K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas pp. 271-271(1) Authors: Sugio K.; Kishimoto Y.; Virmani A.; Hung J.; Gazdar A.
Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer pp. 271-271(1) Authors: Levin W.; Casey G.; Ramos J.; Arboleda M.; Reissmann P.; Slamon D.
Detection of intratumoral DNA heterogeneity in primary lung cancer using a multiple sampling method pp. 272-272(1) Authors: Mizobuchi K.; Fujita Y.; Hashikura H.; Arimoto T.; Nakagaki Y.; Goto T.
Analysis of DNA ploidy with bronchoscopic brushing specimen as a diagnostic aid for lung cancer pp. 272-272(1) Authors: Kim Y.; Lee S.; Chung I.; Kang Y.; Choi I.; Park K.
Correlation of p53 protein overexpression, gene mutation with prognosis in resected non-small cell lung cancer (NSCLC) patients pp. 272-272(1) Authors: Lee Y.; Shin D.; Kim J.; Lim H.; Chung K.; Yang W.
Lack of tissue specificity of mucin markers in a lung cancer model: Biochemical approach pp. 272-272(1) Authors: Bombardieri E.; Seregni E.; Bogni A.; Botti C.; Maffioli L.; Lombardo C.
Somatostatin receptor expression in lung cancer pp. 272-273(2) Authors: O'Byrne K.; Halmos G.; Pinski J.; Groot K.; Szepeshazi K.; Schally A.
Retinoblastoma protein in non-small cell lung carcinoma, cells arrested for growth by retinoic acid pp. 273-273(1) Author: Maxwell S.
Retinoblastoma protein expression in lung cancer: An immunohistochemical analysis pp. 273-273(1) Authors: Higashiyama M.; Doi O.; Kodama K.; Yokouchi H.; Tateishi R.
Co-localization of three neuropeptides and NADPH diaphorase in a small cell lung carcinoma cell line pp. 273-273(1) Authors: Fabien N.; Cespuglio R.; Burlet S.; Pages M.; Paulin C.
Absence of p16(INK4) protein is restricted to the subset of lung cancer lines that retains wildtype RB pp. 273-273(1) Authors: Otterson G.; Kratzke R.; Coxon A.; Kim Y.; Kaye F.
Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history pp. 273-274(2) Authors: Dosaka-Akita H.; Shindoh M.; Fujino M.; Kinoshita I.; Akie K.; Katoh M.; Kawakami Y.
The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer pp. 274-274(1) Authors: Vignaud J.-M.; Marie B.; Klein N.; Plenat F.; Pech M.; Borrelly J.
Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval pp. 274-274(1) Authors: Testa J.; Siegfried J.; Liu Z.; Hunt J.; Feder M.; Litwin S.
Proliferating cell nuclear antigen and Ki-67 in lung carcinoma: Correlation with DNA flow cytometric analysis pp. 274-274(1) Authors: Kawai T.; Suzuki M.; Kono S.; Shinomiya N.; Rokutanda M.; Takagi K.
Genetic alterations in p53 and K-Pas in lung cancer in relation to histopathology of the turner and smoking history of the patient pp. 274-274(1) Authors: Ridanpaa M.; Karjalainen A.; Anttila S.; Vainio H.; Husgafvel-Pursiainen K.
Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model pp. 274-275(2) Authors: Fujiwara T.; De Wei Cai Georges R.; Mukhopadhyay T.; Crimm E.; Roth J.
Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs pp. 275-275(1) Authors: Kawashima K.; Shikama H.; Imoto K.; Izawa M.; Naruke T.; Okabayashi K.
Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas pp. 275-275(1) Authors: Gaudino G.; Cirillo D.; Naldini L.; Rossino P.; Comoglio P.
Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression pp. 275-275(1) Authors: Fontanini G.; Vignati S.; Bigini D.; Merlo G.; Ribecchini A.; Angeletti C.
Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue pp. 275-275(1) Authors: Schraml P.; Shipman R.; Colombi M.; Ludwig C.
Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas pp. 275-275(1) Authors: Gouyer V.; Gazzeri S.; Brambilla E.; Bolon I.; Moro D.; Perron P.
Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types pp. 276-276(1) Authors: Alexandrie A.-K.; Sundberg M.; Seidegard J.; Tornling G.; Rannug A.
Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid pp. 276-276(1) Authors: Maxwell S.; Mukhopadhyay T.
Distribution pattern of the basement membrane components is one of the significant prognostic correlates in peripheral lung adenocarcinomas pp. 276-276(1) Authors: Matsui K.; Kitagawa M.; Sugiyama S.; Yamamoto K.
Clinical study of primary lung cancer with sarcomatous components pp. 276-276(1) Authors: Daido K.; Arita K.; Ejima T.; Satoh R.; Fujiwara M.; Nambu S.
Cytologic characterization of bronchial epithelial changes in small cell carcinoma of the lung pp. 276-276(1) Authors: Boucher L.; Yoneda K.
Cytologic features of peripheral squamous cell carcinoma of the lung pp. 276-276(1) Authors: Kamiya M.; Uei Y.; Shimosato Y.
A phase II study testing weekly platinum derivative combination chemotherapy as second-line treatment in patients with advanced small cell lung cancer pp. 277-277(1) Authors: Sculier J.P.; Thiriaux J.; Bureau G.; Lafitte J.J.; Recloux P.; Brohee D.
Lung cancer pathology in smokers, ex-smokers and never smokers pp. 277-277(1) Authors: Muscat J.; Wynder E.
Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas: An immunohistochemical study with ultrastructural correlations pp. 277-277(1) Authors: Loy T.; Darkow G.; Quesenberry J.
Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung pp. 277-277(1) Authors: Yamashiro K.; Yasuda S.; Nagase A.; Hirata T.; Nojima T.; Nagashima K.
Are pathologists biased by clinical information? A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma pp. 277-277(1) Authors: Skov B.; Braendstrup O.; Hirsch F.; Lauritzen A.; Nielsen H.; Skov T.
The value of neuroendocrine markers in non-small cell lung cancer: A comparative immunohistopathologic study pp. 277-278(2) Authors: Kiriakogiani-Psoropoulou P.; Malamou-Mitsi V.; Martinopoulou U.; Legaki S.; Tamvakis N.; Vrettou E.
Comparison of autopsy, clinical and death certificate diagnosis with particular reference to lung cancer. A review of the published data pp. 278-278(1) Author: Lee P.
The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma pp. 278-278(1) Authors: Grove A.; Paulsen S.; Gregersen M.
Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas pp. 278-278(1) Authors: Loy T.; Calaluce R.
Pulmonary blastomas. Report on two cases and literature review pp. 278-278(1) Authors: Schmidt W.; Leifeld H.; Hoer P.; Dewald-Schmidt M.
Advances in pathobiological research on lung carcinoma pp. 278-278(1) Author: Noguchi M.
Impact of neuroendocrine differentiation in non-small cell lung cancer: The LCSG experience pp. 278-278(1) Authors: Linnoila R.; Piantadosi S.; Ruckdeschel J.
The correlation between bronchoscopic morphology and pathologic type in bronchogenic carcinoma pp. 279-279(1) Authors: Lee H.; Yoo C.; Kim Y.; Han S.; Shim Y.-S.; Kim K.
Differentiation of adenocarcinoma of the lung and malignant mesothelioma: Predictive value and reproducibility of immunoreactive antibodies pp. 279-279(1) Authors: Guldhammer Skov B.; Lauritzen A.; Hirsch F.; Skov T.; Nielsen H.
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer pp. 279-279(1) Authors: Passlick B.; Izbicki J.; Kubuschok B.; Nathrath W.; Thetter O.; Pichlmeier U.
Pathology of the pulmonary arteries in malignant neoplasms of the lung pp. 279-279(1) Authors: Fisseler-Eckhoff A.; Muller K.-M.
An expert system for teaching cytopathologic diagnosis of lung cancers pp. 279-279(1) Authors: Balko J.; Tao L.-C.
The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies pp. 279-280(2) Authors: Guinee D.; Fishback N.; Koss M.; Abbondanzo S.; Travis W.
Cytochemical studies to determine the histogenesis in anaplastic or poorly differentiated pulmonary tumours pp. 280-280(1) Authors: Pisiriciler R.; Yerci O.; Topalidis T.
Bronchogenic carcinoma presenting as a pseudopregnancy pp. 280-280(1) Authors: Manzi D.; Greenberg B.; Maier D.; Forouhar F.; Malchoff C.
The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods pp. 280-280(1) Authors: Buccheri G.; Ferrigno D.
The role of intraoperative ultrasound in lung cancer patients pp. 280-280(1) Authors: Herman K.; Kolodziejski L.
An autopsy case of lung cancer metastasizing to renal cell cancer and rectal villous adenoma pp. 280-280(1) Authors: Takiguchi Y.; Kasamatsu N.; Hashizume I.; Hanzawa S.; Sasaki K.; Baba M.
Treatment of brain metastases from primary lung cancer pp. 280-281(2) Authors: Ryan G.; Ball D.; Smith J.
Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer pp. 281-281(1) Authors: Izbicki J.; Passlick B.; Karg O.; Bloechle C.; Pantel K.; Knoefel W.
Carcinoid tumors of the lung: Do atypical features require aggressive management? pp. 281-281(1) Authors: Marty-Ane C.-H.; Costes V.; Pujol J.-L.; Alauzen M.; Baldet P.; Mary H.
Coaching persons with lung cancer to report sensory pain: Literature review and pilot study findings pp. 281-281(1) Authors: Wilkie D.; Williams A.; Grevstad P.; Mekwa J.
Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer pp. 281-281(1) Authors: O'Shea P.; Cassidy M.; Freaney R.; McCarthy P.; Fennelly J.
Percutaneous balloon pericardiotomy for management of cardiac tamponade in a patient with lung cancer and large pericardial effusion pp. 281-282(2) Authors: Kouvaras G.; Polydorou A.; Hatziantoniou G.
Small giant cell carcinoma of the lung diagnosed preoperatively by transthoracic aspiration cytology: A case report pp. 282-282(1) Authors: Nonomura A.; Mizukami Y.; Shimizu J.; Watanabe Y.; Kobayashi T.; Kamimura R.
Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations pp. 282-282(1) Authors: Pasini F.; Pelosi G.; Mostacci R.; Santo A.; Masotti A.; Spagnolli P.
A case of synchronous multiple lung cancer with heterogeneous histological types pp. 282-282(1) Authors: Akiyama Y.; Kondo H.; Miyazaki M.; Horiuchi N.; Shirono R.; Fujii Y.
Small cell carcinoma of the lung resembling pleural mesothelioma pp. 282-282(1) Authors: Nomura M.; Fujimura M.; Matsuda T.; Nakamura Y.; Takayanagi N.; Kitagawa M.
A case of tracheal cancer following completion pneumonectomy for double primary lung cancer pp. 282-282(1) Authors: Hatta T.; Ohyabu H.; Kurisu S.; Matsuda S.; Kodama A.; Eno K.
A case of small cell lung cancer with both sarcoid reaction and metastasis in the regional lymph nodes pp. 282-282(1) Authors: Inagaki M.; Akaogi E.; Mitsui K.; Ishikawa S.; Yamamoto T.; Ogata T.
Prognostic factors of primary lung cancer. Assessment of tumor doubling time in survival pp. 282-282(1) Authors: Usuda K.; Saito Y.; Aikawa H.; Chen Y.; Endo C.; Takahashi S.
Spontaneous regression of a lung carcinoma. A case report and review of the literature pp. 282-283(2) Authors: Martinez-Albaladejo M.; Garcia-Lopez B.; Alguacil-Garcia G.; Gonzalez-Pina B.; De Paco Moya M.
Bronchioloalveolar carcinoma with bronchorrhoea treated with erythromycin pp. 283-283(1) Authors: Suga T.; Sugiyama Y.; Fujii T.; Kitamura S.
Diagnostic yield of transthoracic needle aspiration biopsy following negative fiberoptic bronchoscopy in 103 patients with peripheral circumscribed pulmonary lesions pp. 283-283(1) Authors: Milman N.; Faurschou P.; Grode G.
Solitary pulmonary nodule: Preliminary study of evaluation with incremental dynamic CT pp. 283-283(1) Authors: Yamashita K.; Matsunobe S.; Tsuda T.; Nemoto T.; Matsumoto K.; Miki H.
Interobserver variation in the computed tomographic evaluation of mediastinal lymph node size in patients with potentially resectable lung cancer pp. 283-283(1) Authors: Guyatt G.; Lefcoe M.; Walter S.; Cook D.; Troyan S.; Griffith L.
Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer pp. 283-283(1) Authors: Okada T.; Kawashima K.; Fukushi S.; Minakuchi T.; Nishimura S.
Small cell lung carcinoma in a young patient of only 17 years old. A case report pp. 283-283(1) Authors: Robinet G.; Gouva S.; Le Reste N.; Leroy J.; Brambilla E.; Clavier J.
Lipid pneumonia and associated bronchio-alveolar carcinoma pp. 284-284(1) Authors: Breton J.; Jeffredo Y.; Ranfaing E.; Clement F.; Faure E.; Garnier G.
MR imaging of bronchogenic carcinoma pp. 284-284(1) Author: Zhang Z.-Q.
Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay pp. 284-284(1) Authors: Takada M.; Masuda N.; Matsuura E.; Kasunoki Y.; Matui K.; Nakagawa K.
CYFRA 21-1: A new tumor marker for lung cancer? pp. 284-284(1) Authors: Lequaglie C.; Marino P.; Maioli C.; Preda F.; Ravasi G.
Analysis of the energy balance in lung cancer patients pp. 284-284(1) Authors: Staal-Van den Brekel A.; Schols A.; Ten Velde G.; Buurman W.; Wouters E.
Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production pp. 284-284(1) Authors: Winquist E.; Laskey J.; Crump M.; Khamsi F.; Shepherd F.
Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years pp. 285-285(1) Authors: Johnson B.; Linnoila R.; Williams J.; Venzon D.; Okunieff P.; Anderson G.
The value of bone marrow examination in small cell carcinoma of the lung pp. 285-285(1) Authors: Horlyck A.; Henriques U.; Jakobsen A.
A case report of pulmonary squamous cell carcinoma accompanying myasthenia gravis pp. 285-285(1) Authors: Tomoyasu H.; Tanimura S.; Bamba J.
TNF- determination in serum and pleural effusion in patients with lung cancer pp. 285-285(1) Authors: Scagliotti G.; Gatti E.; Ferrari G.; Mutti L.; Pozzi E.
Bronchogenic carcinoma in HIV-positive patients: Findings on chest radiographs and CT scans pp. 285-285(1) Authors: Fishman J.; Schwartz D.; Sais G.; Flores M.; Sridhar K.
Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer pp. 285-285(1) Authors: Jebb S.; Osborne R.; Dixon A.; Bleehen N.; Elia M.
Metastasis in tongue from carcinoma of bronchus: A case report pp. 286-286(1) Authors: Shehab Z.; Desousa S.; Pahor A.
Fluoroscopically guided fine needle pulmonary biopsy using the ROTEX needle: Results from 890 patients with focal lung lesions pp. 286-286(1) Authors: Szolar D.; Preidler K.; Kugler C.; Hausegger K.; Klein G.; Popper H.
Videothoracoscopy and video-assisted small thoracotomy for the treatment of pulmonary malignancies pp. 286-286(1) Authors: Casadio C.; Giobbe R.; Cianci R.; Molinatti M.; Oliaro A.; Maggi G.
A case of adenocarcinoma of the lung successfully treated by combination chemotherapy with cisplatin and vindesine, resulting in a long survival without recurrence and synchronous thyroid cancer pp. 286-286(1) Authors: Harita S.; Kimura Y.; Okazaki M.
Small cell lung cancer presenting as a metastatic conjunctival tumor pp. 286-286(1) Authors: Gotoh T.; Tsujimoto S.; Hashimoto S.; Arimoto T.; Iwasaki Y.; Hiramori N.
Measurable or assessable disease in lung cancer trials: Does it matter? pp. 286-286(1) Authors: Jett J.; Su J.; Krook J.; Goldberg R.; Kugler J.
Preoperative evaluation of stage I and stage II non-small cell lung cancer pp. 286-287(2) Authors: Hatter J.; Kohman L.; Mosca R.; Graziano S.; Veit L.; Coleman M.
Prediction of probability of pneumonectomy for lung cancer using Tc-99m MAA perfusion lung imaging pp. 287-287(1) Authors: Chen C.-Y.; Kao C.-H.; Hsu N.-Y.; Chen C.-L.; Hsu C.-P.; Wang P.-Y.
Prognostic significance of tissue polypeptidespecific antigen (TPS) in patients with advanced non-small cell lung cancer pp. 287-287(1) Authors: Van der Gaast A.; Schoenmakers C.; Kok T.; Blijenberg B.; Hop W.; Splinter T.
Clinical evaluation of serum tissue polypeptidespecific antigen (TPS) in non-small cell lung cancer pp. 287-287(1) Authors: Pujol J.-L.; Cooper E.; Grenier J.; Purves D.; Lehmann M.; Ray P.
The clinical significance serum N-POMC level in lung cancer patients pp. 287-287(1) Authors: Li L.; Luo W.; Lu Z.
Survival analysis of untreated patients with non-small-cell lung cancer pp. 287-287(1) Authors: Vrdoljak E.; Mise K.; Sapunar D.; Rozga A.; Marusic M.
Endoscopic criteria of early squamous cell carcinoma of the bronchus pp. 287-287(1) Authors: Akaogi E.; Ogawa I.; Mitsui K.; Onizuka M.; Ishikawa S.; Yamamoto T.
Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma pp. 287-288(2) Authors: Kirsch C.-M.; Von Pawel J.; Grau I.; Tatsch K.
The role of CT and MRI in staging of the mediastinum pp. 288-288(1) Author: Grover F.
The early detection of second primary lung cancers by sputum immunostaining pp. 288-288(1) Authors: Tockman M.; Erozan Y.; Gupta P.; Piantadosi S.; Mulshine J.; Ruckdeschel J.
The adverse effect of perioperative blood transfusion in lung cancer pp. 288-288(1) Authors: Piantadosi S.; Moores D.; McKneally M.
p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871 pp. 288-288(1) Authors: Carbone D.; Mitsudomi T.; Chiba H.; Piantadosi S.; Rusch V.; Nowak J.
Role of mediastinal staging of lung cancer pp. 288-288(1) Author: Thomas P.
A case of primary signet ring cell carcinoma of the lung pp. 289-289(1) Authors: Choi W.; Sohn J.; Kwon O.; Hur J.; Hwang J.; Han S.
Bronchogenic carcinoma: Utility of CT in the evaluation of patients with suspected lesions pp. 289-289(1) Authors: Primack S.; Kyung S.; Logan P.; Miller R.; Muller N.
Bronchioloalveolar cell carcinoma in solitary pulmonary nodule (SPN) with cavitary lesion pp. 289-289(1) Authors: Shim J.; Lee J.; Cho J.; Ihn K.; Yoo S.; Kang K.
Gingival metastasis as first sign of an undifferentiated carcinoma of the lung pp. 289-289(1) Authors: Peris K.; Cerroni L.; Paoloni M.; Margiotta V.; Chimenti S.
Clinical significance of S-phase fraction in small cell lung cancer pp. 289-289(1) Authors: Kim H.; Jung B.; Jeong E.
Inter-relationships between single carbon units' metabolism and resting energy expenditure in weight-losing patients with small cell lung cancer. Effects of methionine supply and chemotherapy pp. 289-289(1) Authors: Sengelov H.; Hansen O.; Simonsen L.; Bulow J.; Nielsen O.; Ovesen L.
Case report; metastasis of lung adenocarcinoma simulating a falx meningioma pp. 289-289(1) Authors: Akiyama Y.; Inagawa S.; Koide T.; Kojima M.; Kumai J.; Nishikawa M.
NDPK/nm23 expression and its correlation with lymph node metastasis in human lung cancer pp. 290-290(1) Authors: Lei W.; Zhang R.; Yan S.
CYFRA 21-1: Preliminary experiences in bronchial carcinoma and other tumors pp. 290-290(1) Authors: Hoefliger M.; Morant R.; Riesen W.; Baumgartner G.; Engler H.
Evaluation of intrapulmonary nodules by positron emission tomo-graphy pp. 290-290(1) Authors: Knopp M.; Bischoff H.
A case of small cell lung cancer associated with fulminant hepatitis B pp. 290-290(1) Authors: Watanabe Y.; Tanaka H.; Ogawa M.; Tanaka T.; Tanizawa M.
A case of peripheral epidermoid carcinoma showing a fungus ball-like shadow pp. 290-290(1) Authors: Komiya T.; Matsushima T.; Kimura M.; Koyama I.
A case of synchronous quadruple lung cancer pp. 290-290(1) Authors: Furukawa T.; Koyanagi K.; Soejima Y.; Sugihara M.; Yoshida T.
A case of G-CSF producing lung cancer detected on examination for leucocytosis pp. 290-290(1) Authors: Kokubo M.; Ishikawa K.; Tateyama K.; Sugiyama A.; Katayama M.; Takami T.
A case of rapidly growing primary lung cancer producing alphafetoprotein pp. 290-290(1) Authors: Kubota M.; Tsubota N.; Yoshimura M.; Murotani A.; Sakamoto T.
Diagnosis of mediastinal lymph node metastasis from primary lung cancer on MR imaging with the STIR technique - Reevaluation of usefulness: Comparison with CT, conventional MRI and MRI with the STIR technique pp. 291-291(1) Authors: Fujimoto K.; Meno S.; Abe T.; Edamitsu O.; Nishimura H.; Hayabuchi N.
Clinicopathological characteristics of tumor doubling time in primary lung cancer pp. 291-291(1) Authors: Usuda K.; Saito Y.; Aikawa K.; Sakurada A.; Chen Y.; Endo C.
The prognostic value of argyrophil nucleolar organizer regions (AgNORs) and fibronectin antibody in stage I lung cancer pp. 291-291(1) Authors: Gomibuchi M.; Kanno S.; Masaki Y.; Haraguchi S.; Tanaka S.; Shoji T.
Clinicopathologic features of small cell lung cancer presenting as a solitary pulmonary nodule pp. 291-291(1) Authors: Yamaji Y.; Yamadori I.; Fujita T.; Fujita J.; Takahara J.; Maeda M.
Features and significance of nonbacterial thrombotic endocarditis in patients with lung cancer pp. 291-291(1) Authors: Tamura A.; Matsubara O.; Komatsu H.; Mohri M.; Katayama T.
Anatomic basis of lymphatic spread of lung carcinoma to the mediastinum: Anatomo-clinical correlations pp. 291-292(2) Authors: Riquet M.; Manac'h D.; Dupont P.; Dujon A.; Hidden G.; Debesse B.
Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: Comparison of in situ hybridization and the polymerase chain reaction pp. 292-292(1) Authors: Popper H.; El-Shabrawi Y.; Wockel W.; Hofler G.; Kenner L.; Juttner-Smolle F.
Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma pp. 292-292(1) Authors: Demirer T.; Ravits J.; Aboulafia D.
CT demonstration of calcification in carcinoma of the lung pp. 292-292(1) Authors: Grewal R.; Austin J.
Lung cancer with skin metastasis pp. 292-292(1) Authors: Terashima T.; Kanazawa M.
The value of combined assay of serum lung cancer associated anti-gens 3C9Ag and WLA-Ag1 pp. 292-292(1) Author: Bai X.-F.
Diffuse infiltrating pulmonary neoplasm with an analysis of 43 cases pp. 292-292(1) Author: Zheng J.-X.
A suspected case of T0N1M0 small cell carcinoma of the lung pp. 292-293(2) Authors: Nakamura K.; Isobe T.; Okusaki K.; Niitani K.; Murakami I.; Yoshida Y.
Squamous cell carcinoma of the lung: Does the nm23 gene expression correlate to the tumor stage? pp. 293-293(1) Authors: Huwer H.; Engel M.; Welter C.; Dooley S.; Kalweit G.; Feindt P.
Transforming growth factor-beta 1 (TGF-1)- and 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer pp. 293-293(1) Authors: Maeda J.; Ueki N.; Ohkawa T.; Iwahashi N.; Nakano T.; Hada T.
Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer pp. 293-293(1) Authors: Lewis P.; Griffin S.; Marsden P.; Gee T.; Nunan T.; Malsey M.
Pulmonary carcinoma metastatic to the larynx pp. 293-293(1) Authors: Bernaldez R.; Toledano A.; Alvarez J.; Gavilan J.
The value of measuring serum TPA levels in bronchopulmonary cancer. A comparative study with ACE, CA 19.9 and NSE levels pp. 293-293(1) Authors: Prevost A.; Passemard F.; Perdu D.; Vallerand H.; Deschamps F.; Lavaud F.
Adenocarcinoma of the lung with unusual invasion of metastases into the pericardium pp. 293-293(1) Authors: Haberbosch W.; Bohle R.; Oksche A.; Waas W.; Heinrichs C.; Morr H.
Tumor angiogenesis in human lung adenocarcinoma pp. 293-294(2) Authors: Yamazaki K.; Abe S.; Takekawa H.; Sukoh N.; Watanabe N.; Ogura S.
Tumor doubling time and prognostic assessment of patients with primary lung cancer pp. 294-294(1) Authors: Usuda K.; Saito Y.; Sagawa M.; Sato M.; Kanma K.; Takahashi S.
Serological tumor markers for small cell lung cancer and their therapeutic implications pp. 294-294(1) Author: Vangsted A.
Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer pp. 294-294(1) Authors: Icard P.; Regnard J.-F.; Essomba A.; Panebianco V.; Magdeleinat P.; Levasseur P.
Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose pp. 294-294(1) Authors: Scott W.; Schwabe J.; Gupta N.; Dewan N.; Reeb S.; Sugimoto J.
Ability to culture resectable non-small cell lung carcinomas is correlated with recurrence pp. 294-295(2) Authors: Siegfried J.; Davis A.; Testa J.; Hunt J.; Keenan R.; Yousem S.
Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumours? pp. 295-295(1) Authors: White P.; Adams H.; Crane M.; Butchart E.
A small cell bronchogenic carcinoma associated with tumoral hypophosphataemia and inappropriate antidiuresis pp. 295-295(1) Authors: Robin N.; Gill G.; Van Heyningen C.; Fraser W.
Prognostic value of a 90kD subunit containing glycoprotein tumor-associated antigen specific immune complexes in lung cancer patients pp. 295-295(1) Authors: Gupta R.; Morton D.
Gastrointestinal metastases from lung cancer: Report of a case pp. 295-295(1) Authors: Liu N.-J.; Chiu C.-T.; Wu S.-S.; Lin S.-M.; Chen P.-C.; Wu C.-S.
Prostatic metastasis of a small cell lung cancer in a young male pp. 295-295(1) Authors: Madersbacher S.; Schatzl G.; Susani M.; Maier U.
Assessment of bone marrow involvement by magnetic resonance imaging in small cell lung cancer: No significant change of staging pp. 295-296(2) Authors: Milleron B.; Le Breton C.; Carette M.; Cadranel J.; Akoun G.
Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer pp. 296-296(1) Authors: Ferrigno D.; Buccheri G.
Role of determination of serum zinc, copper, and copperzinc ratio in evaluating diagnosis, therapeutic effect and prognosis of lung cancer pp. 296-296(1) Author: Zhang Z.-T.
Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC) pp. 296-296(1) Authors: Jorgensen L.; Osterlind K.; Hansen H.; Cooper E.
The value of octreotide scintigraphy in patients with lung cancer pp. 296-296(1) Authors: Kwekkeboom D.; Kho G.; Lamberts S.; Reubi J.-C.; Laissue J.; Krenning E.
Lung adenocarcinoma and metastasis in cavernous bodies of the penis pp. 296-296(1) Authors: Ocio F.C.; Velez F.F.; Gorospe F.G.; Santos F.M.; Alfos L.G.
Fiberscopic diagnosis in lung cancer. A report of 45 cases pp. 296-296(1) Author: Hu J.-Z.
Combined thoracoscopy and mediastinoscopy for the evaluation of mediastinal lymph node metastasis in left upper lobe lung cancer pp. 297-297(1) Authors: Nakanishi R.; Mitsudomi T.; Osaki T.
Basic and clinical studies on serum cytokeratin 19 fragment assay using centocor(R) CYFRA 21-1 kit in patients with lung cancer pp. 297-297(1) Authors: Hamase A.; Sugimoto Y.; Maeda M.; Kitani H.; Fukuchi M.
Early and long-term results after completion pneumonectomy pp. 297-297(1) Authors: Massard G.; Lyons G.; Wihlm J.-M.; Fernoux P.; Dumont P.; Kessler R.
Pneumonectomy after contralateral lobectomy: Is it reasonable? pp. 297-297(1) Authors: Vaaler A.; Hosannah H.; Wagner R.
Some problems of tracheobronchoplasty for lung cancer in a Regional Hospital in Russia pp. 297-297(1) Authors: Orzheshkovsky O.; Reshetov A.; Gridnev A.; Grinchenko S.; Makrinova O.
Incidence of local recurrence and second primary tumors in resected stage I lung cancer pp. 297-298(2) Authors: Martini N.; Bains M.; Burt M.; Zakowski M.; McCormack P.; Rusch V.
Long-term antimicrobial prophylaxis in lung cancer surgery: Correlation between microbiological findings and empyema development pp. 298-298(1) Authors: Ratto G.; Fantino G.; Tassara E.; Angelini M.; Spessa E.; Parodi A.
A new procedure for right upper lobectomy of lung with recon-struction of the carina pp. 298-298(1) Author: Ding J.-A.
Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection pp. 298-298(1) Authors: Isobe T.; Hiyama K.; Yoshida Y.; Fujiwara Y.; Yamakido M.
Evaluation of prognostic significance of p53 gene alterations in patients with surgically resected lung cancer pp. 298-298(1) Authors: Kashii T.; Mizushima Y.; Lima C.; Noto H.; Sato H.; Saito H.
Quality-of-life following thoracotomy for lung cancer pp. 298-298(1) Authors: Dales R.; Belanger R.; Shamji F.; Leech J.; Crepeau A.; Sachs H.
Bronchoplastic procedures for lung cancer: Clinical study in 136 patients pp. 299-299(1) Authors: Kawahara K.; Akamine S.; Tsuji H.; Nakamura A.; Takahashi T.; Tagawa Y.
One hundred and one cases of bronchoplasty for primary lung cancer pp. 299-299(1) Authors: Tsubota N.; Yoshimura M.; Murotani A.; Miyamoto Y.; Matoba Y.
Management of regionally advanced (stage III) non-small cell lung cancer: LCSG 831 pp. 299-299(1) Author: Eagan R.
Current status of surgical resection for lung cancer pp. 299-299(1) Author: Pearson E.
General principles of surgery quality control pp. 299-299(1) Author: Holmes E.
Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer pp. 299-299(1) Authors: Deslauriers J.; Ginsberg R.; Piantadosi S.; Fournier B.
Quality of life in lung cancer surgical adjuvant trials pp. 299-299(1) Authors: Ruckdeschel J.; Piantadosi S.H.
Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma pp. 300-300(1) Author: Holmes E.
What were the issues of surgical importance in lung cancer treatment in 1977; and how did they change over time? pp. 300-300(1) Author: McKneally M.
Surgery for bronchogenic carcinoma in the elderly: Immediate re-sults pp. 300-300(1) Authors: Di Giorgio A.; Arnone P.; Casali G.; Canavese A.; Cardini C.; Speciale R.
Lung cancer surgery: A critical review of the evidence pp. 300-300(1) Authors: Lederle F.; Niewoehner D.
Comparative evaluation of relative survival versus classical methods applied to patients with non small cell lung cancer pp. 300-300(1) Authors: Foucher P.; Coudert B.; Dramais-Marcel D.; Arveux P.; Camus P.; Jeannin L.
Bilateral synchronous muscle-sparing thoracotomy in the manage-ment of bilateral pulmonary neoplasms pp. 300-300(1) Authors: Brulatti M.; Gelsomini S.; Tonielli E.; Del Prete P.; Guernelli N.
Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption pp. 301-301(1) Authors: Walsh G.; Morice R.; Putnam J.; Nesbitt J.; McMurtrey M.; Ryan M.
Preoperative risk evaluation for lung cancer resection: Predicted postoperative product as a predictor of surgical mortality pp. 301-301(1) Authors: Pierce R.; Copland J.; Sharpe K.; Barter C.
Surgery for brain metastases from nonsmall cell lung carcinomas and tissue cultures from the resected specimens pp. 301-301(1) Authors: Kodama K.; Doi O.; Higashiyama M.; Yokouchi H.; Nakagawa H.; Mori Y.
Surgery for bronchogenic cancer in patients 75 and over pp. 301-301(1) Authors: Manac'h D.; Riquet M.; Dujon A.; Le Pimpec-Barthes F.; Debrosse D.; Debesse B.
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer pp. 301-302(2) Authors: Miller V.; Rigas J.; Francis P.; Grant S.; Pisters K.; Venkatraman E.
Chemotherapy in small cell lung carcinoma. Prognostic value of complete response in 12800 patients pp. 302-302(1) Authors: Lebeau B.; Chastang C.; Schuller M.; Thiberville L.; Vaylet F.; Derenne J.
Small cell lung cancer (SCLC): A randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alfa-interferon or no treatment, as maintenance therapy pp. 302-302(1) Authors: Tummarello D.; Graziano F.; Mari D.; Cetto G.; Pasini F.; Antonio S.
Radical radiotherapy for early nonsmall cell lung cancer pp. 302-302(1) Authors: Graham P.; Gebski V.; Langslands A.
Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer? pp. 302-302(1) Authors: Pfeiffer P.; Sorensen P.; Rose C.
Combination of cisplatin and interferon-2a (RoferonR-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study pp. 303-303(1) Authors: Kataja V.; Yap A.
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer pp. 303-303(1) Authors: Ellis P.; Smith I.; Hardy J.; Nicolson M.; Talbot D.; Ashley S.
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer pp. 303-303(1) Authors: Bitran J.; Green M.; Perry M.; Hollis D.; Herndon J.
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer pp. 303-303(1) Authors: Schiller J.; Morgan-Ihrig C.; Levitt M.
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine pp. 303-304(2) Authors: Joss R.; Alberto L.; Hurny C.; Bacchi M.; Leyvraz S.; Thurlimann B.
Effect of coenzyme Q10 and azelastin on protecting radiation pneumonitis with lung cancer pp. 304-304(1) Authors: Imanaka K.; Izumiyama K.; Sakaguchi T.; Kushima T.; Okamoto Y.; Kono M.
Cyclocreatine in cancer chemotherapy pp. 304-304(1) Authors: Teicher B.; Menon K.; Northey D.; Liu J.; Kufe D.
Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line pp. 304-304(1) Authors: Song E.-J.; Yang V.; Chiang C.; Chao C.-K.
Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation pp. 304-304(1) Authors: Prendiville J.; Lorigan P.; Hicks F.; Leahy B.; Stout R.; Burt P.
The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts pp. 304-304(1) Authors: Van der Graaf W.; Mulder N.; Meijer C.; De Vries E.
Dose intensity of the CAVE regimen in small cell lung cancer correlates to response rate pp. 305-305(1) Authors: Sirzea F.; Westberg R.; Lewensohn R.; Billing B.
A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer pp. 305-305(1) Authors: Furuse K.; Kubota K.; Kawahara M.; Ogawara M.; Kinuwaki E.; Motomiya M.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: A regimen associated with major toxicity in patients with advanced non-small cell lung cancer pp. 305-305(1) Authors: Klastersky J.; Sculier J.; Ries F.; Dabouis G.; Libert P.; Schmerber J.
Standard vs. high-dose epirubicin in combination chemotherapy of small cell lung cancer (SCLC)-Results of a phase III randomized trial pp. 305-305(1) Authors: Kolaric K.; Oreskovic B.; Vukas D.; Cepulic E.; Dicic M.; Judina S.
Role of mdr1 and p53 expression in the chemoresistance of lung carcinomas pp. 305-305(1) Authors: Peoc'h M.; Brambilla E.; Moro D.; Gazzeri S.; Brambilla C.
Carboplatin plus oral etoposide in elderly patients with non small cell lung cancer. A study of the 'Groupe francais de pneumocancerologie' (GFPC) pp. 305-306(2) Authors: Castelnau O.; Perol M.; Vergnenegre A.; Blanchon F.; Arnaud A.; Taytard A.; Guerin J.C.; Bonnaud F.; Kleisbauer J.P.
Efficacy of combination multidrug chemotherapy (mitomycin, ifosfamide and cisplatin) and radiotherapy for treatment of brain metastases in non small cell lung cancer pp. 306-306(1) Authors: Cumin I.; Lacroix H.; Mahe M.; Dutin J.; Dabouis G.
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: A FONICAP randomised phase II study pp. 306-306(1) Authors: Ardizzoni A.; Addamo G.; Baldini E.; Borghini U.; Portalone L.; De Marinis F.
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines pp. 306-306(1) Authors: Eijdems E.; De Haas M.; Timmerman A.; Van Der Schans G.; Kamst E.; De Nooij J.
Cytotoxic effect of herbal medicine Sho-saiko-to on human lung cancer cell lines in vitro pp. 306-306(1) Authors: Mizushima Y.; Kashii T.; Tokimitsu Y.; Kobayashi M.
Phase III study of a combination regimen composed of cisplatin, carboplatin and etoposide against small cell lung cancer pp. 306-306(1) Authors: Ichiki M.; Sakurai M.; Hayashi I.
Acquired resistance and cross-resistance of gemcitabine to cisplatin or vindesine in human lung cancer xenografted in nude mice pp. 306-306(1) Authors: Fujita F.; Fujita M.; Fujita M.; Sakamoto Y.
Carboplatin and etoposide in extensive small cell lung cancer pp. 307-307(1) Authors: Viren M.; Liippo K.; Ojala A.; Helle L.; Hinkka S.; Huovinen R.
Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief In patients treated with cisplatin, vinblastine and mitomycin-C pp. 307-307(1) Authors: Tummarello D.; Graziano F.; Isidori P.; Cellerino R.
In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice pp. 307-307(1) Authors: Heike Y.; Takahashi M.; Ohira T.; Arioka H.; Funayama Y.; Nishio K.
Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone pp. 307-307(1) Authors: Lorusso V.; Pezzella G.; Catino A.; Guida M.; Scoditti S.; Lorenzo R.
Inhaled recombinant interferon gamma in patients with lung cancer: Pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and mono-cytes pp. 307-307(1) Authors: Halme M.; Maasilta P.; Repo H.; Ristola M.; Taskinen E.; Mattson K.
Comparative activity of navelbine, navelbine + cisplatin, and vin-desine + cisplatin in the therapy of unresectable non small cell lung carcinoma. Results of a multicentric European randomized trial including 612 patients pp. 307-307(1) Authors: Gonzalez Larriba J.; Alberola V.; Lianes P.; Panizo A.; Carrato A.; Munoz Quintana A.
Treatment of Non-Small cell lung cancer with ifosfamide (IFO) + 4'-Epiadriamycin (EPI) + platinum vs. IFO + EPI: A GETLAC study pp. 307-308(2) Authors: Bracato N.; Bruno M.; Araujo C.; Cervellino J.; Pirisi C.; Temperley G.
Phase II clinical trial of didemnin B in previously treated small cell lung cancer pp. 308-308(1) Authors: Shin D.; Holoye P.; Forman A.; Winn R.; Perez-Soler R.; Dakhil S.
Late phase II clinical study of RP56976 (Docetaxel) in patients with non-small cell lung cancer pp. 308-308(1) Authors: Kudo S.; Hino M.; Fujita A.; Igarashi T.; Arita K.; Niitani H.
Early phase II clinical study of RP56976 (Docetaxel) in patients with primary pulmonary cancer pp. 308-308(1) Authors: Yokoyama A.; Kurita Y.; Watanabe K.; Negoro S.; Ogura T.; Nakano M.
Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice pp. 308-308(1) Authors: Fujita F.; Fujita M.; Fujita M.; Sakamoto Y.
New promising anticancer drugs for lung cancer pp. 308-308(1) Authors: Ariyoshi Y.; Sugiura T.
Approaches to the analysis of quality of life data: Experiences gained from a medical research council lung cancer working party palliative chemotherapy trial pp. 308-309(2) Authors: Hopwood P.; Stephens R.; Machin D.
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer pp. 309-309(1) Authors: Oberli-Schrammle A.; Joncourt F.; Stadler M.; Altermatt H.; Buser K.; Ris H.
Plasma 5-fluorouracil and -fluoro--alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil pp. 309-309(1) Authors: Thiberville L.; Compagnon P.; Moore N.; Bastian G.; Richard M.; Hellot M.
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer pp. 309-309(1) Authors: Ihde D.; Mulshine J.; Kramer B.; Steinberg S.; Linnoila R.; Gazdar A.
Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation pp. 309-309(1) Authors: Thomas G.; Barrand M.; Stewart S.; Rabbitts P.; Williams E.; Twentyman P.
Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases pp. 309-310(2) Authors: Shi T.; Yan J.
Response rate of small cell lung cancer treated with CE-CAP alternating chemotherapy pp. 310-310(1) Authors: Zhang X.; Sun Y.; Liu Y.
Gene expression of somatostatin receptor sybtypes, SSTR1 and SSTR2, in human lung cancer cell lines pp. 310-310(1) Authors: Fujita T.; Yamaji Y.; Sato M.; Murao K.; Takahara J.
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer pp. 310-310(1) Authors: Masuda N.; Fukuoka M.; Kudoh S.; Matsui K.; Kusunoki Y.; Takada M.
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study pp. 310-310(1) Authors: Anderson H.; Lund B.; Bach F.; Thatcher N.; Walling J.; Hansen H.
Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: A cancer research campaign trial pp. 310-311(2) Authors: Souhami R.; Rudd R.; Ruiz de Elvira M.-C.; James L.; Gower N.; Harper P.
Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer pp. 311-311(1) Authors: Sugita T.; Matsunaga K.; Kobayashi H.; Horikawa S.; Suzuki Y.; Nishiyama H.
Vinorelbine (Navelbine) in non-small cell lung cancer: Future directions pp. 311-311(1) Author: Crawford J.
A phase II study of cisplatin, 5-fluorouracil, and leucovorin aug-mented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: Rationale and study design pp. 311-311(1) Authors: Vokes E.; Drinkard L.; Samuels B.; Hoffman P.; Watson S.; Bitran J.
Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor pp. 311-311(1) Authors: Crawford J.; O'Rourke M.; Coltman C.
Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer pp. 311-312(2) Authors: Viallet J.; Ayoub J.; Rousseau P.; Souhami L.; Hohneker J.; Shepherd F.
Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report pp. 312-312(1) Authors: Vokes E.; Rosenberg R.; Jahanzeb M.; Craig J.; Gralla R.; Belani C.
A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis pp. 312-312(1) Authors: Le Chevalier T.; Pujol J.-L.; Douillard J.-Y.; Alberola V.; Monnier A.; Riviere A.
Vinorelbine (Navelbine)-A new agent for the treatment of non-small cell lung cancer: A summary pp. 312-312(1) Author: Coltman C.
Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer pp. 312-312(1) Authors: Murray N.; Coppin C.; Coldman A.; Pater J.; Rapp E.
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer pp. 313-313(1) Authors: Jett J.; Maksymiuk A.; Su J.; Mailliard J.; Krook J.; Tschetter L.
Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer pp. 313-313(1) Authors: Pujol J.-L.; Hayot M.; Rouanet P.; Le Chevalier T.
Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells pp. 313-313(1) Authors: Mulder H.; Lankelma J.; Dekker H.; Broxterman H.; Pinedo H.
DT-diaphorase as a determinant of sensitivity to adriamycin in non-small-cell lung-cancer cell lines pp. 313-313(1) Authors: Kasahara K.; Shibata K.; Bando T.; Numata Y.; Fujimura M.; Matsuda T.
Synergic action with octreotide and chemotherapy in Small-Cell Lung Cancer: A pilot study pp. 313-314(2) Authors: Soresi E.; Invernizzi G.; Boffi R.; Liuzzi A.; Borghini U.; Mantellini P.
Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: A randomised study pp. 314-314(1) Authors: Veronesi A.; Cartei G.; Crivellari D.; Magri M.; Della Valentina M.; Foladore S.
Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice pp. 314-314(1) Authors: Aabo K.; Vindelov L.; Christensen I.; Spang-Thomsen M.
Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells pp. 314-314(1) Authors: Smith P.; Soues S.; Gottlieb T.; Falk S.; Watson J.; Osborne R.
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice pp. 314-315(2) Authors: Pinski J.; Schally A.; Halmos G.; Szepeshazi K.; Groot K.; O'Byrne K.
Comparison of effect of I.V. cisplatin (DDP) with I.V. carboplatin (CDP) in the treatment of advanced lung cancer under maximum tolerance dosages (MTD) pp. 315-315(1) Author: Hua X.-M.
Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer pp. 315-315(1) Authors: Klastersky J.; Sculier J.
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: A European cancer centre effort pp. 315-315(1) Authors: Giaccone G.; Huizing M.; Huinink W.; Koolen M.; Postmus P.; Van Kralingen K.
Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer pp. 315-315(1) Authors: Sculier J.-P.; Paesmans M.; Libert P.; Bureau G.; Dabouis G.; Thiriaux J.
Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer pp. 315-315(1) Authors: Gabazza E.; Taguchi O.; Yamakami T.; Machishi M.; Ibata H.; Suzuki S.
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines pp. 316-316(1) Authors: Favoni R.; Ravera F.; Pirani P.; Ardizzoni A.; Noonan D.; de Cupis A.
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro pp. 316-316(1) Authors: Woll P.; Rozengurt E.
Late phase II clinical study of KW-2307 in previously untreated patients with non-small cell lung cancer pp. 316-316(1) Authors: Furuse K.; Kinuwaki E.; Motomiya M.; Nishiwaki H.; Hasegawa K.; Kobayashi K.
Bronchial arterial hemodynamics after thoracic irradiation therapy in lung cancer patients pp. 316-316(1) Authors: Nambu Y.; Tamamura H.; Ohguchi M.; Mouri M.; Kobayashi Y.; Yamanouchi K.
Establishment of a human small-cell lung-cancer subline resistant to okadaic acid pp. 316-316(1) Authors: Takeda Y.; Nishio K.; Kubota N.; Miura K.; Morikage T.; Ohmori T.
Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer pp. 316-317(2) Authors: Robert F.; Wheeler R.; Molthrop D.; Bailey A.; Chen S.
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells pp. 317-317(1) Authors: Versantvoort C.; Broxterman H.; Lankelma J.; Feller N.; Pinedo H.
Palliative endobronchial brachytherapy for central lung tumors: A prospective, randomized comparison of two fractionation schedules pp. 317-317(1) Authors: Huber R.; Fischer R.; Hautmann H.; Pollinger B.; Wendt T.; Muller-Wening D.
Comparative assessment of three radiotherapy treatment protocols for inoperable cerebral metastases of non-small cell lung carcinoma pp. 317-317(1) Authors: Demange L.; Franks A.; Panis X.
Intraluminal irradiation in the treatment of malignant airway obstruction pp. 317-317(1) Authors: Kohek P.; Pakisch B.; Glanzer H.
International survey of radiotherapy practice for radical treatment of non-small cell lung cancer pp. 317-317(1) Authors: Van Houtte P.; Gregor A.; Philips P.
Three-dimensional conformal radiotherapy in bronchogenic carcinoma: Considerations for implementation pp. 317-318(2) Authors: Emami B.; Graham M.; Purdy J.
High dose rate intraluminal radiotherapy for carcinoma of the bronchus: Outcome of treatment of 406 patients pp. 318-318(1) Authors: Gollins S.; Burt P.; Barber P.; Stout R.
Hyperfractionated irradiation for non-small cell lung cancer (NSCLC) - A phase II clinical trial pp. 318-318(1) Authors: Fu S.; Jiang G.; Wang L.
Radiation thrapy for irresectable non-small-cell lung cancer. Preliminary results of a randomized study pp. 318-318(1) Authors: Exposito J.; Linares A.; Cano C.; Del Moral R.; Martinez M.; Hernandez V.
Postoperative radiation for lung cancer metastatic to the brain pp. 318-318(1) Authors: Armstrong J.; Wronski M.; Galicich J.; Arbit E.; Leibel S.; Burt M.
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: Analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases pp. 318-319(2) Authors: Shaw E.; Su J.; Eagan R.; Jett J.; Maksymiuk A.; Deigert F.
The role of radiotherapy in the treatment of stage III non-small cell lung cancer: A survey of clinical practices in Lombardy, Italy, by the Airo-Lombardia Cooperative Group pp. 319-319(1) Authors: Palazzi M.; Valdagni R.; Poli M.; Buffoli A.; Leoni M.; Vavassori V.
The bronchoscopic brachytherapy in early stage lung cancer of hilar type pp. 319-319(1) Authors: Ono R.; Hirano H.; Kaneko M.
Radiotherapy planning for lung cancer: Can we do better? pp. 319-319(1) Authors: Atkinson C.; Hamilton C.; Wynne C.
Changes in plasma TGF levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis pp. 319-319(1) Authors: Anscher M.; Murase T.; Prescott D.; Marks L.; Reisenbichler H.; Bentel G.
Treatment of small cell lung cancer with combined modality treatment pp. 319-319(1) Author: Hirano A.
Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer pp. 319-320(2) Authors: Jeremic B.; Shibamoto Y.; Acimovic L.; Djuric L.
Current treatment of forms of small-cell bronchial carcinoma limited to the hemithorax pp. 320-320(1) Authors: Quoix E.; Jung G.; Schumacher C.; Morand G.; Pauli G.
A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: An interim toxicity analysis of the first 100 patients pp. 320-320(1) Authors: Ball D.; Bishop J.; Smith J.; Crennan E.; O'Brien P.; Davis S.
Concurrent chemo-radiotherapy for stage III non-small cell lung cancer pp. 320-320(1) Authors: Inoue R.; Takada Y.; Obayashi K.; Kado T.; Yamamoto H.; Hirota S.
Carboplatin, epirubicin, etoposide and thoracic radiotherapy in the treatment of localized small cell lung cancer pp. 320-320(1) Authors: Felip E.; Gallardo E.; Del Campo J.; Vidal R.; Vera R.; Bodi
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor sup-port for advanced malignancies of the chest pp. 320-321(2) Authors: Vokes E.E.; Haraf D.J.; Drinkard L.C.; Hoffman P.C.; Ferguson M.K.; Vogelzang N.J.
Combined-modality treatment of small-cell lung cancer: Randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest pp. 321-321(1) Authors: Joss R.; Alberto P.; Bleher E.; Ludwig C.; Siegenthaler P.; Martinelli G.
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer pp. 321-321(1) Authors: Choy H.; Akerley W.; Safran H.; Clark J.; Rege V.; Papa A.
Combined chemotherapy and radiotherapy: From biology to bed-side pp. 321-321(1) Authors: Hennequin C.; Favaudon V.; Balosso J.; Marty M.; Maylin C.
Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): A review pp. 321-321(1) Author: Mirimanoff R.
The role of induction chemotherapy before radiation therapy in non-operative management of stage III NSCLC pp. 321-322(2) Author: Green M.
Combined multimodality treatment for non-small cell lung cancer-With special reference to pre- and post-operative adjuvant therapy pp. 322-322(1) Author: Watanabe Y.
Current status of neoadjuvant therapy for non-small cell lung cancer pp. 322-322(1) Author: Falser L.
Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881 pp. 322-322(1) Authors: Wagner H.; Lad T.; Piantadosi S.; Ruckdeschel J.
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer: A phase 2 study of the LCSG pp. 322-322(1) Authors: Weiden P.; Piantadosi S.
A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy pp. 323-323(1) Authors: Lad T.; Piantadosi S.; Thomas P.; Payne D.; Ruckdeschel J.; Giaccone G.
Adjuvant chemotherapy for non-small cell lung cancer pp. 323-323(1) Author: Johnson D.
A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung pp. 323-323(1) Authors: Figlin R.; Piantodasi S.
Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer: An LCSG trial pp. 323-323(1) Authors: Feld R.; Rubinstein I.; Thomas P.
The comparison of CAP chemotherapy and radiotherapy to radio-therapy alone for resected lung cancer with positive margin or in-volved highest sampled paratracheal node (stage IIIA): LCSG 791 pp. 323-323(1) Author: Lad T.
Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung: LCSG 773 pp. 323-323(1) Author: Weisenburger T.
A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung: LCSG protocol 771 pp. 323-324(2) Author: Gail M.
Re-evaluation of bronchogenic carcinoma after X-ray and chemo-therapy. The role of CT and MRI pp. 324-324(1) Authors: Gualdi G.; Minerva R.; Volpe A.; Polettini E.; Anaveri G.
Clinical assessment of postoperative immunochemotherapy for non-small cell lung cancer pp. 324-324(1) Authors: Ishii N.; Miyamoto Y.; Okada M.; Tubota N.; Yoshimura M.; Ooyabu H.
Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: Results of a phase II Southwest Oncology Group study pp. 324-324(1) Authors: Hazuka M.; Crowley J.; Bunn P.; O'Rourke M.; Braun T.; Livingston R.
Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B pp. 324-324(1) Authors: Ahles T.; Silberfarb P.; Rundle A.; Holland J.; Komblith A.; Canellos G.
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer pp. 324-324(1) Authors: Comella P.; Scoppa G.; Daponte A.; Musetta G.; Anania C.; Maiorino A.
Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer pp. 325-325(1) Authors: Deutsch M.; Crawford J.; Leopold K.; Wolfe W.; Foster W.; Herndon J.
Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study pp. 325-325(1) Authors: Maggi G.; Casadio C.; Cianci R.; Oliaro A.; Molinatti M.; Bretti S.
Photodynamic therapy of lung cancer pp. 325-325(1) Author: Lam S.
Clarithromycin in the long-term treatment of primary lung cancer. Possibility of clarithromycin as a biological response modifier pp. 325-325(1) Authors: Mikasa K.; Sawaki M.; Kita E.; Hamada K.; Konishi M.; Maeda K.
Inhalation therapy of interferon-gamma against bronchoalveolar carcinoma of the lung; a case report pp. 326-326(1) Authors: Yano T.; Yokoyama H.; Ueda T.; Inoue T.; Asoh H.; Ichinose Y.
Selective embolization of bronchial artery with drug gelfoam in treatment of lung cancer pp. 326-326(1) Author: He D.-X.
Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene pp. 326-326(1) Authors: Osaki T.; Tanio Y.; Tachibana I.; Hosoe S.; Kumagai T.; Kawase I.
Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection pp. 326-326(1) Authors: Lee Y.-C.; Luh S.-P.; Wu R.-M.; Lee C.-J.
Stent-implantation for stenotic malignant tracheobronchial tumors pp. 326-326(1) Authors: Koller H.; Kreuzer A.; Heller K.; Torzsok L.; Neumann M.I.
The strategy for therapy of lung cancer pp. 326-326(1) Authors: Konaka C.; Nakajima S.; Kato H.
Lung cancer pp. 326-327(2) Authors: Travis W.; Travis L.; Devesa S.
Extrapulmonary small cell carcinoma: A single-institution experience and review of the literature pp. 327-327(1) Authors: Lo R.G.; Canzonieri V.; Veronesi A.; Dal B.V.; Barzan L.; Zancanaro C.
Bronchial and thymic carcinoid tumors: A review pp. 327-327(1) Authors: Dusmet M.; McKneally M.
Treatment of small cell lung cancer pp. 327-327(1) Authors: Ueoka H.; Ohnoshi T.
Recent change of management in advanced non-small cell lung cancer pp. 327-327(1) Authors: Kodama N.; Kawahara M.; Furuse K.
Future directions in clinical research for lung cancer pp. 327-327(1) Author: Bunn P.
Evaluation of the therapeutic prognosis and long-term survivors of small cell lung cancer pp. 327-327(1) Authors: Nakayama H.; Yokoyama A.; Kinameri K.; Kurita Y.
Current management of unresectable non-small cell lung cancer pp. 328-328(1) Authors: Livingston R.; Gralla R.; Coltman C.; Crawford J.; Vokes E.
Small cell lung cancer: Analysis of factors influencing the response to treatment and survival pp. 328-328(1) Authors: De Wet M.; Falkson G.; Rapoport B.
Treatment of advanced non-small cell lung cancer pp. 328-328(1) Author: Shepherd F.
Practical approaches to the treatment of patients with extensive stage small cell lung cancer pp. 328-328(1) Authors: Greco F.; Hainsworth J.
Quality of life in patients with lung cancer pp. 328-328(1) Authors: Pavlovic N.; Pavlovic M.
Should we reestablish the lung cancer study group? pp. 328-329(2) Author: Rusch V.
Evaluation of a decision-support system for inoperable non-small cell lung cancer pp. 329-329(1) Authors: Wigren T.; Kolari P.
Shopping cart
RSS for latest issue
Print this page
Print this page
Print this page